Biogen Stock News

Aduhelm was the tipping point for Biogen''s turmoil, but STAT''s reporting reveals much deeper problems at the company, rooted in years of corporate tension and bitter disputes about its strategic

Cardinal Capital Management reduced its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 0.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,496 shares of the biotechnology company’s stock after selling 59 shares during the period. Cardinal […]

Biogen's intrinsic value currently matches the value the stock market has placed on it. If you purchase Biogen at this price, you get their pipeline for free.

Arkadios Wealth Advisors decreased its stake in Biogen Inc. (NASDAQ:BIIB) by 9.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,391 shares of the biotechnology companys stock after selling 152 shares during the period. Arkadios Wealth Advisors holdings in Biogen were []

Chevy Chase Trust Holdings Inc. reduced its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 4.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 92,231 shares of the biotechnology companys stock after selling 4,432 shares during the []

The global Neurodegenerative Disease market size is projected a CAGR of 3.4% during 2021-2027. The rising frequency of neurological illnesses, more public awareness, and a robust product pipeline for neurodegenerative disease treatment are all driving the growth of the neurodegenerative

NEXT Financial Group Inc lifted its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 292.8% during the third quarter, Holdings Channel reports. The fund owned 601 shares of the biotechnology company’s stock after purchasing an additional 448 shares during the quarter. NEXT Financial Group Inc’s holdings in Biogen were worth $170,000 as of its most […]

Robeco Institutional Asset Management B.V. raised its position in shares of Biogen Inc. (NASDAQ:BIIB) by 4.7% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 172,161 shares of the biotechnology companys stock after buying an additional 7,716 shares during the period. Robeco Institutional Asset Management B.V.s holdings in Biogen were worth $48,722,000 at the []

Barclays Stick to Their Hold Rating for Biogen

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) major shareholder Biogen Inc. sold 28,884 shares of the companys stock in a transaction dated Friday, November 26th. The stock was sold at an average price of $8.60, for a total transaction of $248,402.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through []

Yes -- at least partially.

Yesterday, in Biogen v. Mylan, the Federal Circuit ruled that claims in Biogen''s U.S. patent 8,399,514 (the ''514 patent) were invalid under 35 U.S.C. §112 for failing to satisfy the written description requirement.

Sage Therapeutics (SAGE) and partner Biogen (BIIB) announce positive data from a cohort of an ongoing phase III study, currently evaluating their investigational major depressive disorder drug zuranol